Refined histopathological predictors of BRCA1 and BRCA2 mutation status: a large-scale analysis of breast cancer characteristics from the BCAC, CIMBA, and ENIGMA consortia. - Wikidata - wikimedia - TriplyDB

Refined histopathological predictors of BRCA1 and BRCA2 mutation status: a large-scale analysis of breast cancer characteristics from the BCAC, CIMBA, and ENIGMA consortia.

Refined histopathological predictors of BRCA1 and BRCA2 mutation status: a large-scale analysis of breast cancer characteristics from the BCAC, CIMBA, and ENIGMA consortia.

http://www.wikidata.org/entity/Q35155449

about

"OMIC" tumor markers for breast cancer: A review BRCA1 p.His1673del is a pathogenic mutation associated with a predominant ovarian cancer phenotype.Identification of BRCA1 Deficiency Using Multi-Analyte Estimation of BRCA1 and Its Repressors in FFPE Tumor Samples from Patients with Triple Negative Breast Cancer.Levels of DNA Methylation Vary at CpG Sites across the BRCA1 Promoter, and Differ According to Triple Negative and "BRCA-Like" Status, in Both Blood and Tumour DNA.Revertant mosaicism for family mutations is not observed in BRCA1/2 phenocopies DNA methylation profiling to assess pathogenicity of BRCA1 unclassified variants in breast cancer.BRCA1 and BRCA2 genetic testing-pitfalls and recommendations for managing variants of uncertain clinical significance.Combined genetic and splicing analysis of BRCA1 c.[594-2A>C; 641A>G] highlights the relevance of naturally occurring in-frame transcripts for developing disease gene variant classification algorithms.The fate of BRCA1-related germline mutations in triple-negative breast tumors.Risk algorithms that include pathology adjustment for HER2 amplification need to make further downward adjustments in likelihood scores Classification and Clinical Management of Variants of Uncertain Significance in High Penetrance Cancer Predisposition Genes.Low prevalence of HER2 positivity amongst BRCA1 and BRCA2 mutation carriers and in primary BRCA screens.Impact of germline and somatic BRCA1/2 mutations: tumor spectrum and detection platforms.Genomic analysis of inherited breast cancer among Palestinian women: Genetic heterogeneity and a founder mutation in TP53.Invasive breast carcinomas with ATM gene variants of uncertain significance share distinct histopathologic features.The BRCA2 c.68-7T > A variant is not pathogenic: A model for clinical calibration of spliceogenicity.Cost Effectiveness of Risk-Reducing Mastectomy versus Surveillance in BRCA Mutation Carriers with a History of Ovarian Cancer.Full in-frame exon 3 skipping of BRCA2 confers high risk of breast and/or ovarian cancer.Prevalence of BRCA1 and BRCA2 Mutations Among High-Risk Saudi Patients With Breast Cancer Inherited Breast Cancer in Nigerian Women A Dietary Intervention to Lower Serum Levels of IGF-I in Mutation Carriers Inhibition of Estrogen Signaling Reduces the Incidence of -associated Mammary Tumor Formation

P2860

Q26773092-E9355EA9-C4AD-48B3-97A2-20457F222669 Q33618422-1D21D26C-0FC5-403D-BB09-A47AC7CAB005 Q35989438-7C23E3C9-2B62-49EF-964F-FDDC65B7C9CB Q36087198-3B77D591-AA7F-4D6E-A60E-5F9EB116F56C Q36281144-BC5B8074-7CCF-4E6B-B3BD-B5B3509FA4AB Q36833424-0D6C5416-5054-4ACF-88D3-78D8159B5CA0 Q37220433-1100689B-C4C3-4914-B790-0DDEDC533419 Q37368000-383334FA-C8E2-4E19-A91A-69421BFACABC Q37596828-BCD8B12C-E7D0-4FD9-996D-855DBA7715C2 Q37710182-59141D3A-6DF3-4040-A246-CB012F8A87D7 Q38700025-F0E14A75-AE27-44B9-91C8-776508CE2AC7 Q40903518-7DD4A299-37C5-4622-81F8-1F2FB2D65254 Q45870377-8D1EFD7B-0E06-4F7D-A221-1E1FB735A1B0 Q47769154-FC9D8000-CBF9-496D-AFD9-5503D067C346 Q47846573-E0A5884B-5920-41A3-A6F5-DDCA27C15D69 Q49817640-BF8B8103-A0ED-4DBB-A2BF-B0EA3246D843 Q51346860-DB346B5F-9C80-449E-AC22-1F473C98B288 Q52715788-AB13C0CD-EEE8-46AE-96B7-59302F0E1F97 Q58692157-5B4B414F-825C-4A07-BC47-0C3CECFA21FA Q58726416-FAEEBBA0-BAB8-4EC0-A4A7-C9ABFA81C002 Q58764289-C1D4820B-4957-4DA8-955A-9100EDB6EB1F Q58786210-CD2C9353-7372-4505-8FB0-CBC67A21141E

P2860

Refined histopathological predictors of BRCA1 and BRCA2 mutation status: a large-scale analysis of breast cancer characteristics from the BCAC, CIMBA, and ENIGMA consortia.

http://www.wikidata.org/entity/Q35155449

description

2014 nî lūn-bûn

@nan

2014 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Refined histopathological pred ...... , CIMBA, and ENIGMA consortia.

@ast

Refined histopathological pred ...... , CIMBA, and ENIGMA consortia.

@en

Refined histopathological pred ...... , CIMBA, and ENIGMA consortia.

@en-gb

type

label

Refined histopathological pred ...... , CIMBA, and ENIGMA consortia.

@ast

Refined histopathological pred ...... , CIMBA, and ENIGMA consortia.

@en

Refined histopathological pred ...... , CIMBA, and ENIGMA consortia.

@en-gb

prefLabel

Refined histopathological pred ...... , CIMBA, and ENIGMA consortia.

@ast

Refined histopathological pred ...... , CIMBA, and ENIGMA consortia.

@en

Refined histopathological pred ...... , CIMBA, and ENIGMA consortia.

@en-gb

P1433

Q35155449-C98257CF-FCA3-4CD8-B70A-3B31BFAAE451

P1476

Q35155449-D2D7E8D2-EBDF-4C38-A938-16CA3ED8DD1C

P2093

Q35155449-017E823E-B1C9-4D86-BE3F-FD6647522748

Q35155449-03959D15-5DB5-43BB-ACF3-0C2928EBA713

Q35155449-05540786-3B98-40DC-A5E5-71B5E23177F2

Q35155449-09C9E955-08D7-4843-8BA8-B27D68B9B555

Q35155449-0B719D4A-1C64-43CA-9FE9-19F5FDFA492C

Q35155449-0EA31B03-6D2F-48C4-A7DE-DD5A1C7E29E4

Q35155449-12BC286F-C024-48CE-AA31-1B4B8F66302C

Q35155449-13096ECA-1770-454A-B96E-D249C7D904C1

Q35155449-16B3660A-3446-4454-A10D-DAABD35C3FFC

Q35155449-1C4C2A7A-3E60-4D41-AEE1-9C8965E60775

P2860

Q35155449-0785E9AD-C5BF-4EA0-81B5-85F85BE46ABB

Q35155449-07BFEBE9-5A13-4772-BC3B-577E1CC393B5

Q35155449-08FE50C6-7AA7-4F45-9535-AE9BA7CA0F57

Q35155449-0BF2FEEF-999B-4659-8C34-D2B2096804DB

Q35155449-0DA77E3C-1DC1-40E9-8BB8-630151354C6A

Q35155449-1217351E-C0E3-40CA-B918-F9148987E0C0

Q35155449-18242C10-D285-40A1-B065-40078472DD76

Q35155449-1ABE7C7F-4B21-4DF5-A4A6-99B95515F97E

Q35155449-26593963-524B-47E1-B9B7-06CA50BE974C

Q35155449-2667FF23-CB94-443E-9DF1-798294331B00

P2888

Q35155449-0A2EC48B-6AFF-4D7A-A9B3-8998DE84F5D6

P304

Q35155449-87478AE1-0574-43B5-8BAE-F1BF44624433

P31

Q35155449-89F6A0FE-F4E8-4C87-8A39-5F3C5D4F09C7

P356

Q35155449-FE7C0A54-E45A-4DEE-A3C9-961B31FC9954

P433

Q35155449-C88BEBAB-8E2E-48B6-B22E-13A6513D0036

P478

Q35155449-F6409F44-6CA8-4481-A029-383CFA3072FD

P50

Q35155449-099EBF06-DF91-4075-8EF6-C4DC91411522

Q35155449-0AC72B16-9600-43A4-9EBF-9166DF34CE49

Q35155449-0C6987F2-C803-499A-9BC0-15F8F5BD5DFB

Q35155449-0D685E18-B185-4658-A407-EAB209F1D1FB

Q35155449-0E65658D-AA5A-4FFB-AF02-6405B557741D

Q35155449-10267531-E392-4682-8A18-5D67811FFDD9

Q35155449-1485767B-4307-427A-9530-7FA53ABE3342

Q35155449-15093B1B-9BD7-49A8-B9CE-09D2CEEFF525

Q35155449-1663A9D7-63F0-444A-89A5-69031F2FE86C

Q35155449-1829F099-F7D7-4650-B4C3-7984706C216D

P577

Q35155449-9F1FDBAA-41BA-4735-AE47-0009E1D42AFF

P5875

Q35155449-0D6F221E-585B-4DDD-AA8F-165D44B26C17

P6179

Q35155449-849B6F8E-DDD7-4E62-8B84-6DAADCEC2689

P698

Q35155449-D6AA5698-CA97-42D8-8B3C-95D0F3A5B18D

P932

Q35155449-CF11E4DB-75B0-42BE-AF0D-735FFF528440

P356

S13058-014-0474-Y

P1433

Breast Cancer Research

P1476

Refined histopathological pred ...... , CIMBA, and ENIGMA consortia.

@en

P2093

ABCTB Investigators

http://www.w3.org/2001/XMLSchema#string

Alexander Miron

http://www.w3.org/2001/XMLSchema#string

Alice S Whittemore

http://www.w3.org/2001/XMLSchema#string

Ana Osorio

http://www.w3.org/2001/XMLSchema#string

Andrew K Godwin

http://www.w3.org/2001/XMLSchema#string

Anita L Bane

http://www.w3.org/2001/XMLSchema#string

Barbara Pasini

http://www.w3.org/2001/XMLSchema#string

Bernardo Bonanni

http://www.w3.org/2001/XMLSchema#string

Beth Y Karlan

http://www.w3.org/2001/XMLSchema#string

Catriona McLean

http://www.w3.org/2001/XMLSchema#string

P2860

Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies

DNA methylome of familial breast cancer identifies distinct profiles defined by mutation status.

Triple-negative breast cancer and PTEN (phosphatase and tensin homologue) loss are predictors of BRCA1 germline mutations in women with early-onset and familial breast cancer, but not in women with isolated late-onset breast cancer.

Estrogen receptor positive breast cancers in BRCA1 mutation carriers: clinical risk factors and pathologic features

Integrated evaluation of DNA sequence variants of unknown clinical significance: application to BRCA1 and BRCA2

Incorporating tumour pathology information into breast cancer risk prediction algorithms.

Germline BRCA mutation evaluation in a prospective triple-negative breast cancer registry: implications for hereditary breast and/or ovarian cancer syndrome testing.

Evolutionary pathways in BRCA1-associated breast tumors.

Genotypic and phenotypic analysis of familial male breast cancer shows under representation of the HER2 and basal subtypes in BRCA-associated carcinomas.

Estrogen receptor status in BRCA1- and BRCA2-related breast cancer: the influence of age, grade, and histological type.

P2888

s13058-014-0474-y

P304

3419

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/S13058-014-0474-Y

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

16

http://www.w3.org/2001/XMLSchema#string

P50

Georgia Chenevix-Trench

Jenny Chang-Claude

Rita Schmutzler

Stephen Chanock

Hoda Anton-Culver

Loic Le Marchand

P577

2014-12-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

274724363

http://www.w3.org/2001/XMLSchema#string

P6179

1029402553

http://www.w3.org/2001/XMLSchema#string

P698

25857409

http://www.w3.org/2001/XMLSchema#string

P932

4352262

http://www.w3.org/2001/XMLSchema#string